Standpoint Research Starts Gilead Sciences (GILD) at Buy

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. DSX
2. GNK
3. INTC
4. SPCX
5. III
6. TTEC
7. DAL
8. AWK
9. BHP
10. MDA

Go back to Standpoint Research Starts Gilead Sciences (GILD) at Buy

Gilead (GILD) Needs Impactful M&A for the Next Leg of Growth - Piper Jaffray

February 3, 2016 9:11 AM EST

Piper Jaffray analyst, Joshua Schimmer, is hoping to see an impactful acquisition to propel Gilead Sciences (NASDAQ: GILD) into its next leg of growth. However, at 7x next year's eps, the stock may have hit bottom.

GILD reported a very strong 4Q15, bolstered by strong HCV sales in Japan, partially offset by limited VA HCV starts in the quarter. The company guided to flat/slightly down product sales in 2016 and a significant uptick in R&D (+12%-23%) and SG&A (+2%-12%). The company is increasing its dividend... More

Gilead Sciences (GILD) Tops Q4 EPS by 32c

February 2, 2016 4:00 PM EST

Gilead Sciences (NASDAQ: GILD) reported Q4 EPS of $3.32, $0.32 better than the analyst estimate of $3.00. Revenue for the quarter came in at $8.51 billion versus the consensus estimate of $8.13 billion.

Product Sales

Total product sales for the fourth quarter of 2015 were $8.4 billion compared to $7.2 billion for the fourth quarter of 2014. In the fourth quarter of 2015, product sales in the U.S. were $4.8 billion compared to $5.5 billion in the fourth quarter of 2014. In Europe, product sales were $1.7 billion compared to $1.4 billion in the fourth quarter of 2014. Sales in other international locations increased to $1.9... More